DE69738300D1 - Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten - Google Patents

Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten

Info

Publication number
DE69738300D1
DE69738300D1 DE69738300T DE69738300T DE69738300D1 DE 69738300 D1 DE69738300 D1 DE 69738300D1 DE 69738300 T DE69738300 T DE 69738300T DE 69738300 T DE69738300 T DE 69738300T DE 69738300 D1 DE69738300 D1 DE 69738300D1
Authority
DE
Germany
Prior art keywords
insulative
pharmaceutical compositions
containing water
delayed release
complex compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738300T
Other languages
English (en)
Other versions
DE69738300T2 (de
Inventor
Malcolm L Gefter
Nicholas Barker
Gary Musso
Christopher J Molineaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praecis Pharmaceuticals Inc
Original Assignee
Praecis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharmaceuticals Inc filed Critical Praecis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69738300D1 publication Critical patent/DE69738300D1/de
Publication of DE69738300T2 publication Critical patent/DE69738300T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
DE69738300T 1996-12-11 1997-12-11 Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten Expired - Lifetime DE69738300T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/762,747 US5968895A (en) 1996-12-11 1996-12-11 Pharmaceutical formulations for sustained drug delivery
US762747 1996-12-11
PCT/US1997/022881 WO1998025642A2 (en) 1996-12-11 1997-12-11 Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery

Publications (2)

Publication Number Publication Date
DE69738300D1 true DE69738300D1 (de) 2007-12-27
DE69738300T2 DE69738300T2 (de) 2008-09-04

Family

ID=25065930

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69738460T Expired - Lifetime DE69738460D1 (de) 1996-12-11 1997-12-11 Pharmazeutische Zusammensetzung mit verzögerter Freisetzung, die wasserunlösliche Komplexverbindungen enthalten
DE69738300T Expired - Lifetime DE69738300T2 (de) 1996-12-11 1997-12-11 Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69738460T Expired - Lifetime DE69738460D1 (de) 1996-12-11 1997-12-11 Pharmazeutische Zusammensetzung mit verzögerter Freisetzung, die wasserunlösliche Komplexverbindungen enthalten

Country Status (35)

Country Link
US (4) US5968895A (de)
EP (4) EP2316471A1 (de)
JP (3) JP4033498B2 (de)
KR (2) KR20110122773A (de)
CN (2) CN100522239C (de)
AR (1) AR010351A1 (de)
AT (3) ATE378059T1 (de)
AU (1) AU735174B2 (de)
BR (1) BR9714015A (de)
CA (1) CA2274847A1 (de)
CO (1) CO4910114A1 (de)
CZ (1) CZ301119B6 (de)
DE (2) DE69738460D1 (de)
DK (1) DK1398037T3 (de)
DZ (1) DZ2371A1 (de)
ES (1) ES2299192T3 (de)
HK (2) HK1023282A1 (de)
HR (1) HRP970674A2 (de)
HU (1) HUP0000299A3 (de)
IL (3) IL130309A (de)
JO (1) JO1998B1 (de)
MA (1) MA26456A1 (de)
NZ (4) NZ579443A (de)
PE (1) PE20000008A1 (de)
PL (2) PL200675B1 (de)
PT (1) PT952843E (de)
RU (1) RU2202371C2 (de)
SI (1) SI0952843T1 (de)
SK (1) SK287305B6 (de)
TN (1) TNSN97205A1 (de)
TR (1) TR199901382T2 (de)
UA (1) UA68343C2 (de)
UY (2) UY24806A1 (de)
WO (1) WO1998025642A2 (de)
ZA (1) ZA9710994B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6197337B1 (en) * 1999-05-10 2001-03-06 Kenneth Weisman Therapeutic uses of abarelix
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
KR100452752B1 (ko) * 2000-04-18 2004-10-12 주식회사 펩트론 단백질 함유 서방성 제제를 제조하는 방법 및 그 제제
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US7037889B2 (en) * 2000-09-13 2006-05-02 Praecis Pharmaceuticals Inc. Pharmaceutical compositions for sustained drug delivery
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
WO2002056903A2 (en) * 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
AU2002258563A1 (en) * 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
PL208073B1 (pl) * 2002-09-27 2011-03-31 Aeterna Zentaris Gmbh Żelowy preparat farmaceutyczny oraz sposób jego otrzymywania i zestaw do jego wytwarzania
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
NZ571243A (en) * 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
CA2512052C (en) * 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7833545B2 (en) * 2003-04-29 2010-11-16 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
BR0318454A (pt) 2003-08-08 2006-09-12 Abgenix Inc anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
PT1682537E (pt) 2003-11-05 2012-06-20 Sarcode Bioscience Inc Moduladores de adesão celular
JP5596252B2 (ja) 2003-11-10 2014-09-24 アラーガン、インコーポレイテッド 低用量デスモプレシンを含有する医薬組成物
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US20060067971A1 (en) * 2004-09-27 2006-03-30 Story Brooks J Bone void filler
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006116565A2 (en) * 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
NZ563271A (en) * 2005-04-29 2009-12-24 Cubist Pharm Inc Therapeutic compositions
LT2444079T (lt) 2005-05-17 2017-03-27 Sarcode Bioscience Inc. Kompozicijos ir būdai, skirti akių sutrikimų gydymui
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
WO2007021970A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Stable pharmaceutical formulations and methods of use thereof
DK1999129T3 (da) 2005-10-11 2011-02-07 Intermune Inc Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
AU2006330833A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
CN101484587B (zh) 2006-02-03 2014-02-12 英克隆有限责任公司 Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
US8129414B2 (en) * 2006-06-19 2012-03-06 Adeboye Adejare Non-competitive NMDA receptor antagonists
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
PT2063909E (pt) * 2006-09-19 2013-01-15 Genzyme Corp Formulações para administração terapêutica da hormona estimulante da tiróide (tsh)
WO2008137807A1 (en) * 2007-05-02 2008-11-13 Tyrx Pharma, Inc. Dihydroxybenzoate polymers and uses thereof
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
US8048862B2 (en) 2008-04-15 2011-11-01 Intermune, Inc. Macrocyclic inhibitors of hepatitis C virus replication
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2276508A4 (de) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc Freisetzung von lfa-1-antagonisten gegen das magen-darm-system
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2319158B1 (es) * 2008-12-23 2010-01-26 Grifols, S.A Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2438122A1 (de) 2009-06-02 2012-04-11 Massachusetts Institute of Technology Beschichtungen
US20120058355A1 (en) 2009-06-02 2012-03-08 Hyomin Lee Coatings
PT4104848T (pt) 2009-06-18 2024-01-04 Acerus Pharmaceuticals Usa Llc Administração segura de desmopressina
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX362218B (es) 2011-05-04 2019-01-09 Balance Therapeutics Inc Derivados de pentilentetrazol.
KR102112375B1 (ko) * 2012-05-14 2020-05-18 데이진 가부시키가이샤 방사선 멸균 내성 단백질 조성물
EP3715345B1 (de) 2012-07-25 2024-04-10 Novartis AG Herstellung eines lfa-1-hemmers
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
US11129869B2 (en) * 2013-03-15 2021-09-28 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014202625B2 (en) 2013-05-14 2018-11-08 Scimar Ltd. Hepatic insulin sensitizing substance and test meal for insulin sensitization
CN104418936B (zh) * 2013-08-20 2018-06-05 中国人民解放军军事医学科学院毒物药物研究所 Lhrh拮抗剂衍生物及其药物用途
CA2926691A1 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN108884130B (zh) 2016-01-11 2022-09-13 博士医疗爱尔兰有限公司 用于治疗溃疡性结肠炎的制剂和方法
EP3920899A2 (de) 2019-02-08 2021-12-15 The UAB Research Foundation Immuntherapie zur behandlung und vorbeugung von entzündlichen darmerkrankungen
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
FR2455459A1 (fr) * 1979-05-02 1980-11-28 Sertog Procede d'obtention d'une matrice contenant un principe actif et le liberant progressivement
US4431635A (en) 1979-06-13 1984-02-14 Coy David Howard LH-RH Antagonists
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4547370A (en) 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) * 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
EP0300036A4 (de) * 1987-01-30 1989-06-14 Biomed Res Consultants Ltd Auf vasopressin basierte arzneimittelzubereitungen.
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4801577A (en) 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
JPS63218247A (ja) * 1987-03-06 1988-09-12 Yoshiaki Kawashima 高機能懸濁液
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
JPS63310827A (ja) * 1987-06-15 1988-12-19 Sanwa Kagaku Kenkyusho Co Ltd ニコチン酸誘導体を主剤とする徐放性製剤
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
US4851385A (en) 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
ZA887658B (en) * 1987-10-15 1990-06-27 Syntex Inc Intranasal administration of polypeptides in powdered form
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
DD269785A1 (de) * 1988-02-08 1989-07-12 Univ Dresden Tech Verfahren zur herstellung von aktivitaetsstabilisierten und in ihren pharmakologischen eigenschaften modifizierten peptidderivaten
US5300492A (en) 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
DE68928278T2 (de) * 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
US4992421A (en) 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5171835A (en) 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
US5356630A (en) * 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
US5049395A (en) * 1989-03-09 1991-09-17 Micro Vesicular Systems, Inc. Controlled release vehicle
US4980150A (en) * 1989-04-27 1990-12-25 Zetachron, Inc. Chlorhexidine complex
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
AU653325B2 (en) * 1990-02-12 1994-09-29 Lucky Limited A composition durably releasing bioactive polypeptides
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
WO1994008566A1 (en) * 1992-10-21 1994-04-28 Micro Vesicular Systems, Inc. Entrapment vehicle and method
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
RU2146128C1 (ru) * 1993-01-06 2000-03-10 Кинертон Лимитед Ионный конъюгат с длительным периодом высвобождения пептида, способ синтезирования ионного конъюгата, способ синтезирования микрочастиц
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
NZ260933A (en) * 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
US5413990A (en) 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5582591A (en) * 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
JP3862304B2 (ja) * 1994-09-09 2006-12-27 武田薬品工業株式会社 徐放性製剤
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19712718C2 (de) 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US9609852B2 (en) 2014-06-20 2017-04-04 Brome Bird Care Inc. Lantern shaped bird feeder

Also Published As

Publication number Publication date
DE69738300T2 (de) 2008-09-04
AU5699198A (en) 1998-07-03
EP1398037A3 (de) 2004-04-14
EP1878437A2 (de) 2008-01-16
PL199121B1 (pl) 2008-08-29
US6699833B1 (en) 2004-03-02
IL180450A0 (en) 2007-06-03
EP1878437B1 (de) 2011-07-20
IL130309A0 (en) 2000-06-01
US6180608B1 (en) 2001-01-30
PL200675B1 (pl) 2009-01-30
DE69738460D1 (de) 2008-02-21
AU735174B2 (en) 2001-07-05
UY24806A1 (es) 1998-06-09
SK287305B6 (sk) 2010-06-07
JO1998B1 (en) 1999-05-15
EP0952843A2 (de) 1999-11-03
MA26456A1 (fr) 2004-12-20
SK79399A3 (en) 2000-01-18
BR9714015A (pt) 2000-05-09
HUP0000299A3 (en) 2000-09-28
NZ579443A (en) 2011-07-29
CN1245436A (zh) 2000-02-23
WO1998025642A2 (en) 1998-06-18
EP1398037B1 (de) 2008-01-09
PT952843E (pt) 2008-04-15
UY25030A1 (es) 2001-08-27
US20030171296A1 (en) 2003-09-11
DZ2371A1 (fr) 2002-12-28
NZ336269A (en) 2002-02-01
PL334076A1 (en) 2000-01-31
ES2299192T3 (es) 2008-05-16
US5968895A (en) 1999-10-19
ATE383165T1 (de) 2008-01-15
EP2316471A1 (de) 2011-05-04
HUP0000299A1 (hu) 2000-06-28
KR20110122773A (ko) 2011-11-10
KR20000069432A (ko) 2000-11-25
WO1998025642A3 (en) 1998-07-23
JP2011105760A (ja) 2011-06-02
ZA9710994B (en) 1998-07-10
HRP970674A2 (en) 1998-08-31
ATE378059T1 (de) 2007-11-15
CN100522239C (zh) 2009-08-05
DK1398037T3 (da) 2008-05-26
RU2202371C2 (ru) 2003-04-20
CA2274847A1 (en) 1998-06-18
AR010351A1 (es) 2000-06-07
IL130309A (en) 2007-06-17
KR101114618B1 (ko) 2012-03-05
EP1878437A3 (de) 2008-11-12
HK1023282A1 (en) 2000-09-08
ATE516812T1 (de) 2011-08-15
IL180449A0 (en) 2007-06-03
CN101596306A (zh) 2009-12-09
CZ301119B6 (cs) 2009-11-11
EP1398037A2 (de) 2004-03-17
PE20000008A1 (es) 2000-01-19
NZ537042A (en) 2006-12-22
CO4910114A1 (es) 2000-04-24
JP2007016049A (ja) 2007-01-25
CZ206699A3 (cs) 1999-11-17
TR199901382T2 (xx) 1999-08-23
NZ568189A (en) 2009-09-25
TNSN97205A1 (fr) 2005-03-15
JP4033498B2 (ja) 2008-01-16
SI0952843T1 (sl) 2008-10-31
HK1064918A1 (en) 2005-02-08
UA68343C2 (en) 2004-08-16
JP2000508345A (ja) 2000-07-04
EP0952843B1 (de) 2007-11-14

Similar Documents

Publication Publication Date Title
DE69738300D1 (de) Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
ATE486589T1 (de) Osmotische dosierungsform mit verlängerter wirkstoffabgabe
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
ATA905997A (de) Pharmazeutische zubereitung, die ein mycophenolatsalz enthält
HK1034455A1 (en) Oral pharmaceutical extended release dosage form.
DE68901417D1 (de) Pharmazeutische zusammensetzung.
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE69003568D1 (de) Arzneimittel mit verzoegerter freigabe.
HUP9901779A3 (en) Modified release multiple-units dosage composition
FI901102A0 (fi) Farmaceutiska kompositioner.
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
HUP0102453A3 (en) Adenosine derivatives, their use and pharmaceutical compositions containing the compounds
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
ATE240040T1 (de) Stabilisierte zusammensetzung, die halopropynyl- verbindungen enthält
DE69006094T2 (de) Pharmazeutische Zusammensetzungen.
ITRM940002A0 (it) Composizione orale.
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
DE69614407T2 (de) Pharmazeutische zusammensetzungen
DE69708130T2 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
DE69434210D1 (de) Pharmazeutische antacidzusammensetzung
ZA961983B (en) Bicyclic compounds, preparation thereof and use in pharmaceutical compositions.
DE69717810T2 (de) S1452-tabletten mit schneller freisetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition